High-Sensitivity NeuroPET Scanner Receives FDA 510(k)

May 14, 2009 - The FDA has cleared PhotoDetection Systems’ (PDS) NeuroPET scanner, a system designed to serve the clinical and research needs of the molecular neuro-imaging community.

NeuroPET’s patented wavelength-shifting fiber technology enables ultra high-sensitivity and excellent spatial resolution. Its compact/portable design requires no special site preparation and allows for significantly reduced cost of ownership compared to general-purpose PET scanners. NeuroPET uses very low doses of 18F and 11C tracers to image metabolism, amyloid, and dopaminergic binding in neurological diseases. These tracers are known to be helpful in imaging challenging and costly diseases such as Alzheimer’s, Parkinson’s, neuro-oncology, and neuro-psychiatric disorders.

NeuroPET can complement existing clinical and research efforts with high quality, low cost neuro-imaging capacity and its ultra high-sensitivity performance can allow for more frequent repeat low dose scanning of the same subject to monitor response to therapy.

For more information: www.photodetection.com